The tumor stage can also influence RIPK1 expression levels, for example in HNSCC the metastatic stage shows reduced transcriptional and protein expression levels of RIPK1 compared to primary tumor and this could be associated to epigenetic events such as the methylation status in the RIPK1 promoter. This evidence concerns the gene RIPK1 and head and neck squamous cell carcinoma.